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Prostaglandins (PG) are a family of cellular messengers exerting diverse homeostatic and 
pathophysiologic effects. Recently, several studies reported significant increases of PGI2 and 
PGF2α following inhibition of microsomal PGE synthase-1 (mPGES-1) expression, which 
indicated that PGH2 metabolism might be re-distributed when the PGE2 pathway is blocked. To 
address the determinants that govern the relative amounts of PGs, we developed an in vitro cell-
free method, based on liquid chromatography-tandem mass spectrometry (LC-MS/MS), to 
measure the exact amounts of these PGs formed in response to the addition of recombinant 
isomerases and their selective inhibitors. Our in vitro cell-free assay results were confirmed in 
cells using bone marrow-derived macrophage (BMDM). Initially, we determined the in vitro 
stability of PGH2 and noted that there was spontaneous non-enzymatic conversion to PGD2 and 
PGE2. Microsomal PGE synthase-1 markedly increased the conversion to PGE2 and decreased 
conversion to PGD2. Reciprocally, the addition of hematopoietic (H-PGDS) or lipocalin (L-
PGDS) PGD synthase resulted in a relative increase of PGD2 and decrease of PGE2. A detailed 
titration study showed that the ratio of PGE2/PGD2 was closely correlated with the ratio of PGE 
synthase/PGD synthase. Our re-distribution results also provide the foundation for understanding 
how PGH2 metabolism is re-distributed by the presence of distal isomerases or by blocking the 
major metabolic outlet, which could determine the relative benefits and risks resulting from 





Cyclooxygenase (COX) enzymes, also known as PGH2 synthases, catalyze the 
oxygenation of arachidonic acid (AA) to PGG2, followed by the reduction of PGG2 to PGH2 
which serves as a common substrate for various distal isomerases that generate five distinct 
primary PGs, PGE2, PGD2, PGF2α, PGI2, and thromboxane A2 (TXA2), of which 6-keto-PGF1α 
and TXB2 are the main stable non-enzymatic products of PGI2 and TXA2, respectively (Figure 
1). These PGs consist of a series of extracellular and intracellular messengers that produce 
diverse physiologic effects on pain (Zeilhofer, 2007), inflammation and fever (McAdam et al., 
2000), allergy (Prttipher, 2007), platelets (FitzGerald, 1991), cardiovascular system (Vane, 
1983), cancer growth (Wang et al., 2007), renal function (Hebert et al., 2005), reproduction 
(Weems et al., 2006), and possibly Alzheimer’s disease (McGeer and McGeer, 1999). In many 
cases, different PGs have counter-regulatory effects. For example, in contrast to PGE2, PGD2 in 
the brain has a role in promoting sleep (Smyth et al., 2009). Furthermore, various PGs have the 
potential to both promote and counteract inflammatory processes in the body, especially in acute 
allergic inflammation. Thus, the exact physiologic or pathophysiologic response is dependent on 
the relative amounts of biologically active PG species. 
After the enzymatic conversion of PGH2 was reported (Christ-Hazelhof et al., 1976), 
each PG specific isomerase was discovered and purified, including PGE synthase, PGD 
synthase, PGFα synthase, PGI synthase, and TX synthase. Humans express three isoforms of 
PGE synthase, which are mPGES-1, mPGES-2 and cytosolic PGE synthase (cPGES). Whereas 
mPGES-2 and cPGES are constitutively expressed in vivo, mPGES-1 is of particular interest 
because it has been shown to be the most potent (Tanikawa et al., 2002) among PGE synthases 




(Guay et al., 2004). CAY10526 (4-(benzo[b]thiophen-2-yl)-3-bromo-5-hydroxy-dihydro-furan-
2(3H)-one, C12H7BrO3S) and CAY10589 (2-[[4-[([1,1’-biphenyl]-4-ylmethyl)amino]-6-chloro-2-
pyrimidinyl]thio]-octanoic acid, C25H28ClN3O2S) are synthetic compounds that have been 
reported to be selective inhibitors of mPGES-1 (Guerrero et al., 2007; Koeberle et al., 2008). 
PGD synthase activity is also comprised of two isozymes, H-PGDS and L-PGDS. HQL-79 (4-
(diphenylmethoxy)-1-[3-(1H-tetrazol-5-yl)propyl-piperidine, C22H27N5O) is a selective H-PGDS 
inhibitor (Matsushita et al., 1998), and AT-56 (4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-[4-
(2H-tetrazol-5-yl)butyl]-piperidine, C25H27N5) is reported to be a selective L-PGDS inhibitor 
(Irikura et al., 2009). 
Non-steroidal anti-inflammatory drugs (NSAIDs) competitively interfere with binding of 
the AA substrate to COX enzymes. Treatment with traditional NSAIDs such as aspirin and 
ibuprofen decrease PGE2 biosynthesis by non-selectively inhibiting both COX-1 and COX-2 
(Garavito and Mulichak, 2003). However, serious gastrointestinal toxicity (Smyth et al., 2009) 
occurs at ordinary clinical doses due to their non-selective inhibition of both COX enzymes. 
There are also unintended consequences of selective inhibition of COX pathway enzymes. For 
example, rofecoxib and celecoxib are relatively selective for COX-2 and were developed under 
the assumption that specific inhibition of COX-2 would be anti-inflammatory and analgesic but 
lack gastrointestinal toxicity (Garavito and Mulichak, 2003). However, these COX-2 selective 
inhibitors are associated with an increased risk of hypertension, cardiovascular disease and 
stroke (Grosser et al., 2006; Timmers et al., 2007). This is, at least in part, because inhibition of 
COX-2 also blocks the production of PGI2 and alters the balance between the vasoconstrictive 
properties of TXA2 and vasodilatory properties of PGI2 (Crofford et al., 2000; Bombardier et al., 




COX-2 has redirected efforts to examine the effect of interdiction in the individual downstream 
isomerases of PGH2, especially on the inhibition of mPGES-1 (Guerrero et al., 2007; Mbalaviele 
et al., 2010; Rörsch et al., 2010). Since PGH2 serves as a common substrate for at least five 
distinctive PGs and PGH2 itself is extremely unstable and short-lived, it would be premature to 
consider mPGES-1 as a promising and safe new therapeutic target without further investigation 
and understanding of the effect of inhibition of mPGES-1 on the entire PG cascade. In order to 
address this important issue, we developed an in vitro cell-free assay system using LC-MS/MS to 
measure the formation of PGE2 and PGD2, to determine the global consequence of the addition 
of recombinant isomerases and the impact of selective inhibition on the relative production of 
PGE2 and PGD2 , which was also examined in cells using BMDM. We hypothesized that there 
would be a reciprocal relationship between the production of PGE2 and PGD2 when inhibiting 
their specific isomerases that could be biologically important. 
 
Methods 
Animals. For bone marrow experiments, C57BL/6 mice (6 to 12-wk-old, 25-35 g) were 
purchased from Harlan Laboratories (Indianapolis, IN). Mice were housed in a temperature-
controlled room with a 12:12-h light-dark cycle and given standard chow and tap water. All 
studies involving mice were approved by the Institutional Animal Care and Use Committee and 
complied with the Animal Welfare Act. 
Materials. Ovine COX-1, human recombinant COX-2, human recombinant mPGES-1, 
human recombinant H-PGDS, human recombinant L-PGDS, GSH, CAY10526, CAY10589, 




keto-PGF2α, 13,14-dihydro-15-keto-PGE2, 8-iso PGE2, d4-PGE2 and d4-PGD2 were purchased 
from Cayman Chemicals (Ann Arbor, MI). Hemin, epinephrine, Tris base, hydrogen peroxide, 
citric acid, EDTA, and lipopolysaccharide (LPS) were purchased from Sigma-Aldrich (St. Louis, 
MO). Monosodium phosphate, disodium phosphate, hydrochloric acid, and butylated 
hydroxytoluene (BHT) were purchased from Thermo Fisher Scientific (Rockford, IL). Formic 
acid was purchased from EMD Chemicals (San Diego, CA). Purified water was prepared using a 
Millipore (Billerica, MA) Milli-Q purification system or an ELGA (Saint Maurice Cedex, 
France) PURELAB Ultra purification system. Hanks’ Balanced Salt solution (HBSS), fetal 
bovine serum (FBS), penicillin, and streptomycin were purchased from Invitrogen (Carlsbad, 
CA). Dulbecco’s modified Eagle’s medium (DMEM) was purchased from Mediatech (Manassas, 
VA). All organic solvents were HPLC grade or better and were purchased from Thermo Fischer 
(Rockford, IL), and all other chemicals and solvents were ACS reagent grade, unless stated 
otherwise. 
The in vitro system. All experiments were carried out using an in vitro system based on a 
COX functional assay (Cao et al., 2010; Cao et al., 2011). Briefly, 20 μL of 25 mM GSH for 
mPGES-1 or 20 μL of 10 mM GSH for H-PGDS and L-PGDS was mixed on ice with 138 μL of 
100 mM Tris•HCl buffer (pH 8.0, 37°C). Next, 20 μL of Tris•HCl buffer containing mPGES-1, 
H-PGDS or L-PGDS was added and incubated on ice for 2 min. A 2 μL aliquot of enzyme 
inhibitor in DMSO was added, and the solution was pre-incubated at 37°C in an Eppendorf 
Thermomixer R for 10 min. Each reaction was initiated by adding 20 μL of 20 μM PGH2 (2 µM 
final concentration) in Tris•HCl buffer as substrate and terminated after 30 min by adding 50 μL 
of 2 M HCl. In place of PGH2, 20 µL aliquots of 20 μM PGE2, PGD2, PGF2α, 6-keto-PGF1α, or 




contained the same solution composition but without enzymes. The quantitative controls 
represented the maximum amounts of each prostaglandin that could be formed if PGH2 were 
quantitatively converted to a single product.  After measurement using LC-MS/MS, the ratios of 
the peak areas of each prostaglandin in the experiments to the corresponding quantitative control 
were determined and expressed as percentages of the maximum theoretical yield. 
d4-PGE2 and d4-PGD2 (10 µL; 100 ng/mL each in methanol/water, 50:50, v/v) were 
added as internal standards to correct for sample losses, degradation or changes in mass 
spectrometer response. Each sample was extracted using 800 μL hexane/ethyl acetate (50:50, 
v/v), and the organic phase was removed, evaporated to dryness under nitrogen gas, and 
reconstituted in 100 μL methanol/water (50:50, v/v) immediately prior to quantitative analysis 
using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The peak areas were 
measured by using Applied Biosystems Analyst software (Foster City, CA) and manually 
inspected. The curves and data fitting were plotted by using Graphpad Prism 5 (Mountain View, 
CA), and other calculations were carried out using Excel (Microsoft Office) or Numbers (Apple 
iWork).  
Mass spectrometry. For the quantitative analysis of all prostaglandins except for PGH2, 
HPLC separations were carried out using a Shimadzu (Columbia, MD) Prominence HPLC 
system with a Waters (Milford, MA) XTerra MS C18 (2.1 mm × 50 mm, 3.5 μm) analytical 
column and a 5-min isocratic mobile phase consisting of acetonitrile/aqueous 0.1% formic acid 
(37:63, v/v) at a flow rate of 200 μL/min. As shown in Figure 2, all five derivatives of PGH2 
were resolved to baseline in less than 4 min using these chromatographic conditions. The HPLC 
system was interfaced to an Applied Biosystems API 4000 triple quadrupole mass spectrometer 




an 11-min linear gradient from 33% to 90% acetonitrile in aqueous 0.1% formic acid. Using 
gradient LC-MS/MS, PGH2 eluted at a retention time of 7.7 min. 
The PGs formed abundant [M–H]− carboxylate ions during negative ion electrospray, 
which were fragmented using collision-induced dissociation with nitrogen as a collision gas. The 
collision energy (-24 to -30 V) was optimized for each PG to maximize the formation of product 
ions for detection using selected reaction monitoring (SRM). Isomeric PGE2, PGD2 (Cao et al., 
2008) and PGH2 were measured using a SRM transition of m/z 351 to m/z 271 and the SRM 
transition of m/z 353 to m/z 193 was selected for PGF2α (Dahl and van Breemen, 2010).  The 
SRM transition of m/z 369 to m/z 163 was used for 6-keto-PGF1α, and the transition of m/z 369 to 
m/z 169 was used for the measurement of TXB2. Similarly, the SRM of the transition of m/z 355 
to m/z 275 was selected for the internal standards d4-PGE2 and d4-PGD2 (Cao et al., 2008). 
High resolution negative ion electrospray tandem mass spectra of PGH2 and its 
metabolites were acquired using a Waters Synapt G1 quadrupole time-of-flight (QqTOF) hybrid 
tandem mass spectrometer with a Waters Alliance 2690 HPLC system or a Shimadzu ion trap-
TOF mass spectrometer with a Prominence HPLC system. HPLC separations were carried out as 
described above except that the mobile phase consisted of an 11-min linear gradient from 33% to 
90% acetonitrile in aqueous 0.1% formic acid. 
Cell culture assay. Although the in vitro assay provided information regarding biological 
mechanisms of action, the results might not necessarily reflect in vivo processes or even the 
situation within a cell. Therefore, the BMDM was utilized in which mPGES-1 and H-PGDS (L-
PGDS) could be selectively inhibited in order to observe the re-distribution of PGH2 metabolism. 
BMDM was isolated from the rear legs of sacrificed C57BL/6 mice. The harvested rear 




bone marrow cells were obtained by flushing the tibias and femurs using HBSS and cultured in 
DMEM supplemented with 10% FBS, 10% L929 cell-conditioned (LCC) medium, 100 U/mL 
penicillin and 100 μg/mL streptomycin. After 72 hrs of cultivation, the non-adherent cells were 
removed by changing the medium. Adherent cells were subsequently propagated in culture. Cells 
were split at day 7 by EDTA (1 mM) and plated at a density of 5 × 105/mL into 6-well plate with 
LCC medium. On day 8, the cell culture medium was changed to DMEM medium containing 1% 
FBS, penicillin and streptomycin for 1.5 h prior to the addition of inhibitors CAY10526, 
CAY10589, HQL-79 and AT-56 adding 2 hrs prior to the LPS (1 μg/mL) treatment. Cells were 
incubated with 5% CO2 humidified air at 37°C. The cell supernatants were collected and stored 
at -80°C until analysis after 16 hrs treatment with LPS and with different inhibitors. LPS was 
used to stimulate BMDM to activate COX-2 production and prostaglandin synthesis (Xiao et al., 
2008).  
Each supernatant was spiked with d4-PGE2 and d4-PGD2 as internal standards, and citric 
acid and BHT were then added to prevent free radical-catalyzed peroxidation. PGs were 
extracted using hexane/ethyl acetate. After centrifugation, the upper organic phase was collected 
and evaporated to dryness. Immediately before analysis using LC-MS/MS, each extract was 
reconstituted in methanol/water (Cao et al., 2008). Standards for calibration curves and quality 
control measurements were prepared by spiking cell culture medium with measured amounts of 
PGE2 and PGD2. These standards were then processed as described above. The concentrations of 
PGE2 and PGD2 in these standards ranged from 0.1 to 1000 ng/mL (Cao et al., 2008). 
Statistical analysis. Samples were run in triplicate, and values are expressed as mean ± 
SD. Statistical significance was assessed using one-way analysis of variance (ANOVA), and p-






Validation of enzyme and PGH2 purity. To ensure the purity of each enzyme, ovine 
COX-1, human COX-2, mPGES-1, H-PGDS, and L-PGDS were incubated with AA and PGH2 
at 37°C for 10 min, respectively, and the production of PGs was then determined. Ovine COX-1 
and human COX-2 did not increase the formation of PGE2 or PGD2 from PGH2 compared with 
the control (Figure 3A), suggesting that neither ovine COX-1 or human COX-2 was 
contaminated with PG isomerases. In addition, the isomerases mPGES-1, H-PGD and L-PGDS 
had no effect on the metabolism of AA in the absence of ovine COX-1 or human COX-2 (Figure 
3B), suggesting that these isomerases were not contaminated with either ovine COX-1 or human 
COX-2.  The 2 μM PGH2 solution used in these experiments was also analyzed using LC-
MS/MS and was found to already contain 6.1 ± 1.1 % PGE2, 1.8 ± 0.7 % PGD2 and 0.2 ± 0.1 % 
PGF2α due to non-enzymatic rearrangement. 
In vitro system optimization. PBS buffer (pH 6.0 to 8.0, 37°C) and Tris•HCl (pH 7.0 to 
8.0, 37°C) produced similar results during incubations with PGH2, but Tris•HCl buffer (pH 8.0, 
37°C) produced slightly larger enzymatic yields and is recommended by Cayman Chemicals. 
Therefore, Tris•HCl buffer (pH 8.0, 37°C) was used for all subsequent experiments. GSH has 
been reported to function as an essential co-factor for three isomerases (mPGES-1, H-PGDS, L-
PGDS) (Ouellet et al., 2002; Hohwy et al., 2008; Herlong and Scott, 2005). In our hands, GSH 
enhanced PGs formation only slightly for mPGES-1 and L-PGDS, and it was not essential for the 
function of these enzymes. For H-PGDS, however, GSH was indispensable (Table 1). GSH 




rates significantly. Thus, according to recommendations of the supplier Cayman Chemicals, 2.5 
mM GSH was used for mPGES-1, and 1 mM GSH was used for H-PGDS and L-PGDS. The 
optimal levels of mPGES-1, H-PGDS and L-PGDS were approximately 3 units/μL, 0.1 unit/μL 
and 1 unit/μL, which was at the upper part of the linear range of the dose response curve. A pre-
incubation time of 10 min was used prior to adding the substrate to allow the inhibitors to 
interact fully with the enzyme and to reach maximal inhibition potency (Cao et al., 2010; Cao et 
al., 2011). A reaction time of 30 min was used for enzymatic conversion of PGH2 to PGs. A 
substrate dose-response curve was generated that indicated the production of each PG product 
after 30 min reached a plateau at approximately 4 μM of substrate. A substrate concentration of 2 
μM corresponded to 50% response and was determined to be the Km of the substrate. 
Identification of PGH2 and characterization of unknown derivatives. During the LC-
MS/MS analysis of a PGH2 standard (monitoring the SRM transition of m/z 351 to m/z 271), five 
peaks were observed as shown in Figure 4. The first two peaks were identified according to 
comparison with standards as PGE2 and PGD2, and the last peak was confirmed to be PGH2 
since it continued decreasing while other peaks increased over 160 min (Figure 5). The two 
remaining peaks (retention times 5.7 min and 6.3 min) remain unidentified and are not (by 
comparison with standards) PGI2, 15-keto PGF2α, 13,14-dihydro-15-keto PGE2, or 8-iso PGE2. 
In a separate experiment, the half-life of PGH2 in Tris•HCl buffer at pH 8 and 37°C was 
determined to be 5 min (Figure 6). 
For additional characterization of the unknown peaks, LC-MS/MS analysis was carried 
out using high resolution QqTOF and IT-TOF mass spectrometers. All five compounds separated 
as shown in the chromatogram in Figure 4 were isomeric with identical elemental compositions 




collision energies, all five compounds produced similar tandem mass spectra without any 
characteristic fragmentation that could distinguish them. 
In vitro non-enzymatic conversions of PGH2. Since PGH2 is extremely unstable and 
has a short half-life in aqueous solution, we used LC-MS/MS with SRM to determine the main 
degradation products of PGH2 and their relative yields. In the absence of any enzyme, PGH2 
spontaneously converted to PGE2, PGD2, and a small amount of PGF2α but no 6-keto-PGF1α or 
TXB2. Therefore, neither PGI2 nor TXA2 was spontaneously produced from PGH2. The yields of 
PGE2, PGD2 and PGF2α were approximately 44%, 15% and 1.6%, respectively, with a constant 
ratio among these species of ~3:1:0.1. We observed an unexpected phenomenon after optimizing 
the reaction conditions. There was nearly a 100% increase in PGD2 formation from PGH2 after 
the addition of 1 mM or 2.5 mM GSH, and for PGF2α, there was a 600% increase. However, 
PGE2 formation was slightly decreased or not affected. Moreover, by adding an equivalent 
amount of H2O2, the effect of GSH addition on PGD2 and PGF2α was totally eliminated (Figure 
7A) indicating that reactive oxygen species (ROS) might have a regulatory role in governing the 
relative amounts of these prostaglandins. 
In vitro enzymatic conversions of PGH2. Since PGE2 and PGD2 play significant 
physiological roles in humans and are predominant products of PGH2, we examined the roles in 
their formation of three commercially available human recombinant distal enzymes, mPGES-1, 
H-PGDS and L-PGDS. When the highest concentration of mPGES-1 (300 unit/μL) was 
incubated with PGH2, the yield of PGE2 increased to 62%, whereas PGD2 decreased to 3.6% and 
PGF2α decreased to basal level (Figure 7A). Similarly, when either the highest concentration of 




PGD2 increased to 78%, while the PGE2 formation decreased to 10.8% and PGF2α decreased to 
basal level (Figure 7B). 
We next examined the impact of the addition of pharmacologic inhibitors of these 
downstream enzymes by employing the commercially available mPGES-1 selective inhibitors 
CAY10526 and CAY10589, H-PGDS selective inhibitor HQL-79, and L-PGDS selective 
inhibitor AT-56 in our in vitro system. After incubating PGH2 with mPGES-1 (3 units/μL) and 
300 μM CAY10526 or 100μM CAY10589, PGE2 formation decreased to the basal level 45%, 
whereas PGD2 formation increased to 25%, and PGF2α increased only slightly (Figure 7A). 
Incubation with the H-PGDS specific inhibitor HQL-79 (50 μM) inhibited approximately 90% of 
PGD2 formation (decreased to 26%) in the presence of H-PGDS (0.1 unit/μL), whereas PGE2 
formation increased to 38%, and PGF2α decreased to basal level (Figure 7B). Similarly, the L-
PGDS specific inhibitor AT-56 (100 μM) completely prevented PGD2 formation (decreased to 
24%) when incubating PGH2 with L-PGDS (1 unit/μL), whereas PGE2 formation increased to 
40% and PGF2α decreased to basal level (Figure 7B). The effects of these inhibitors on other 
isomerases were also tested. Surprisingly, CAY10526 and CAY10589 were less specific than 
expected and also inhibited both H-PGDS and L-PGDS in vitro. In contrast, HQL-79 had no 
inhibitory effect on either L-PGDS or mPGES-1, and AT-56 inhibited neither H-PGDS nor 
mPGES-1 (Table 2). 
In vitro re-distribution assay. As obvious shifts of PGH2 to other PGs were observed 
using inhibitors to block their corresponding isomerases, we predicted that there would be re-
distribution in products by inhibition of isomerases that compete for the substrate PGH2. We first 
mixed different volumes of mPGES-1 (3 units/μL) and H-PGDS (0.1 unit/μL) or (L-PGDS, 1 




PGD2 were produced, and vice versa (Figure 8) in a predictable fashion according to the ratio of 
PGES to PGDS activity. We also examined the impact of pharmacologic inhibition with HQL-79 
and AT-56 to further determine the consequence of re-distribution by inhibiting H-PGDS and L-
PGDS, respectively (Figure 9). As expected, by increasing the concentrations of HQL-79 or AT-
56, conversions of PGH2 moved toward the production of PGE2, whereas the production of 
PGD2 decreased. Since our data showed that the purported mPGES-1 inhibitors CAY10526 and 
CAY10589 also strongly inhibited H-PGDS and L-PGDS, re-distribution tests by inhibiting 
mPGES-1 with these agents did not produce re-distribution of PGH2 metabolism in vitro. 
Cell culture re-distribution assay. CAY10526 and CAY10589 did not produce re-
distribution of PGH2 metabolism in BMDM since these agents inhibited not only mPGES-1 but 
also H-PGDS and L-PGDS. AT-56 had no effect on decreasing PGD2 production, which was not 
surprising since L-PGDS protein expression was not detectable in BMDM (Xiao unpublished 
data). Therefore, only H-PGDS was available for inhibition by pharmacologic intervention in 
BMDM. Similar to the in vitro re-distribution assay, treatment of BMDM with the H-PGDS 
inhibitor HQL-79 altered PGH2 conversion toward the production of PGE2, while the production 
of PGD2 decreased (Figure 10). 
 
Discussion 
Previously, we reported that a COX functional assay (Cao et al., 2011) used to screen 
COX-2 selective inhibitors results in production of both PGE2 and PGD2, which raised the 
obvious question as to how PGE2 and PGD2 are produced in the absence of downstream 




isomerases or that it might have some unknown functions which could catalyze conversion of 
PGH2 to PGs. When incubating COX-1 or COX-2 with PGH2 produced no increase in the 
production of the PGs, we then redirected our focus on investigating the stability of the 
intermediate PGH2. These studies showed that PGH2 was extremely unstable in aqueous solution 
in vitro and spontaneously and non-enzymaticly converted to PGE2, PGD2 and PGF2α, with a 
constant ratio of ~3:1:0.1 (Figure 7). This not only provided an explanation for the results in our 
COX functional assay but also clarified the identities and yields of PGH2 products. Based on our 
in vitro findings, it is possible that PGH2 would also convert to PGs in vivo without any 
downstream isomerases, which further brings into question the efficacy of inhibiting PGE2 
formation using mPGES-1 inhibitors. 
The pivotal finding of our study is the PGH2 metabolic re-distribution to other forms of 
PGs by inhibiting either PGE synthase or PGD synthase (Figure 7). A possible explanation is 
that mPGES-1 and H-PGDS compete for the substrate PGH2 so that inhibition of one enzyme 
would shunt PGH2 to the other. In order to prove this explanation, several different approaches 
were used. Titration studies (Figure 8) showed how the conversion of PGH2 was closely 
correlated with the relative levels of PGE synthase and PGD synthase. A similar re-distribution 
phenomenon (from PGD2 to PGE2) was also observed in vitro (Figure 9) when using the H-
PGDS selective inhibitor HQL-79 or the L-PGDS selective inhibitor AT-56, since the major 
outlet PGD2 was blocked. Moreover, the BMDM cell culture study (Figure 10) confirmed the 
PGH2 metabolism re-distribution in cells by inhibiting H-PGDS. Purported to be mPGES-1 
selective inhibitors, CAY10526 and CAY10589 also inhibited PGD synthase and could not be 




reported increases of PGI2 and PGF2α by inhibition of mPGES-1 in mice (Guay et al., 2004; 
Mbalaviele et al., 2010; Rörsch et al., 2010; Trebino et al., 2005). 
In the near future, our observations could probably be used to provide therapeutic 
guidance for diseases involving PGs, because the re-distribution and accumulation of certain 
types of PGs might be beneficial and useful for treatment. For example, higher levels of PGI2 
and PGF2α would be favorable since they have anti-inflammatory effects, and more PGD2 could 
have anti-inflammatory effects (Smyth et al., 2009). Since various PGs can produce opposing 
effects, imbalance among them might cause unexpected problems or risks that must not be 
ignored such as with the use of highly selective COX-2 inhibitors. For instance, an increase of 
PGI2 might cause side effects such as low blood pressure in certain patients and even result in 
certain chronic and fatal diseases which are not easy to observe (Smyth et al., 2009). 
We observed moderate inhibition of PGE2 formation by CAY10526 in vitro, however, 
CAY10526 was reported to be a strong mPGES-1 selective inhibitor (Guerrero et al., 2007). The 
probable reason (Guerrero et al., 2007) is that CAY10526, which caused a significant reduction 
in PGE2 production in the induction phase, did not affect PGE2 formation in the post-induction 
phase, which means that CAY10526 selectively inhibited mPGES-1 protein expression. 
During the identification of PGH2 (Figure 4), two peaks (retention times 5.7 min and 6.3 
min) remained unidentified but were not (by comparison with standards) PGI2, 15-keto PGF2α, 
13, 14-dihydro-15-keto PGE2, or 8-iso PGE2. Some possible structures include the reactive γ-
keto aldehydes, levuglandins E2 (LGE2) and D2 (LGD2) (Boutaud et al., 1999). All of these 
compounds are isomers of PGH2. 
GSH has been reported to be an essential co-factor for mPGES-1 (Ouellet et al., 2002), 




the indispensability of GSH for H-PGDS, but it was not necessary for either mPGES-1 or L-
PGDS in our hands (Table 1). This indicated that GSH was not an essential co-factor for 
mPGES-1 and L-PGDS in our in vitro cell-free assay if these two isomerases were not 
contaminated with GSH. During the non-enzymatic conversion study of PGH2, a 600% increase 
of PGF2α production and an almost 100% increase of PGD2 production were found when adding 
GSH into PGH2 standard in aqueous solution (Figure 7A). It has been reported that GST 
increases PGF2α formation, which mainly results from the GST (glutathione-S-trandferase) 
enzymatic catalysis (Burgess et al., 1987). However, other reducing agents, like GSH, can also 
increase PGF2α production (Christ-Hazelhof et al., 1976; Burgess et al., 1999; Nugteren and 
Christ-Hazelhof, 1980), which indicates that this is a non-enzymatic process, possibly by serving 
as a specific electron donor promoting the conversion of PGH2 to PGF2α (Keeting et al., 1987). 
However, little is known about the increase of PGD2 by adding GSH, which raised our interest in 
the undiscovered differences between PGE2 and PGD2. Since both PGE2 and PGD2 have the 
same elemental composition and similar structure, it is very curious that they behave so 
differently in the presence of GSH or other reagents, and these issues are being addressed by our 
on-going studies. 
In summary, although mPGES-1 inhibitors could be used as alternatives to COX-2 
inhibitors to specifically decrease the amount of PGE2, they could also cause PGH2 metabolism 
re-distribution. Thus, it is necessary to have a full understanding of the mechanisms of action and 
physiological effects of all PGs. The consequences of selective inhibition of one or more 
prostaglandin isomerases determine possible subsequent risks. Recently, mPGES-1 was found to 
be functionally coupled with COX-2 (Murakami et al., 2000), which means that mPGES-1 would 




inhibitors to partially inhibit COX-2 and strongly inhibit mPGES-1 might be a more reasonable 
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Figure 1. Scheme for the metabolism of arachidonic acid (AA) to form different 
prostaglandins (PGs). 
Figure 2. Negative ion electrospray LC-MS/MS SRM chromatograms showing the 
detection of 1 μM PGE2, PGD2, PGF2α, 6-keto-PGF1α, and TXB2 standards in methanol/water 
(50:50, v/v). SRM transitions: 6-keto-PGF1α m/z 369→163 (retention time 1.6 min); TXB2 m/z 
369→169 (retention time 2.2 min); PGF2α m/z 353→193 (retention time 2.7 min); PGE2, PGD2 
m/z 351→271 (retention times 3.2 and 3.7 min, respectively). 
Figure 3. Ovine COX-1, human COX-2, mPGES-1, H-PGDS, and L-PGDS were incubated 
at 37°C for 10 min with substrate PGH2 (A) or AA (B), respectively. PG formation (%) 
represents the sum of all PGs that were detected relative to the theoretical maximum based on the 
substrate PGH2 or AA. All the values are the mean ± SD, n=3. *: p < 0.05, significance 
differences in PGs formation compared with no enzyme (A and B). 
Figure 4. Negative ion electrospray SRM chromatograms of the transition m/z 351 to m/z 
271 showing the detection of 2 μM PGH2 standard in methanol/water (50:50, v/v) at pH 7 and 
4°C, and its non-enzymatic derivatives using an 11-min linear gradient from 33% to 90% 
acetonitrile in aqueous 0.1% formic acid at a flow rate 200 μL/min. PGE2 and PGD2 (retention 
times 4.5 min and 4.8 min) were identified by comparison with standards. PGH2 (retention time 
7.7 min) was identified by monitoring its level over 160 min at pH 7 and 4°C. The remaining 
two peaks (retention times 5.7 min and 6.3 min) remain unidentified but were not (by 




Figure 5. Levels of PGE2 (A), PGD2 (B), PGH2 (E) and two unknown compounds (C and 
D) formed over 160 min from an initial concentration of 2 μM PGH2 in methanol/water (50:50, 
v/v) at pH 7 and 4°C. The formation of PGE2 and PGD2 was constant during the first 50 min and 
reached a plateau by 70 min (A and B), while the amount of PGH2 continued to decrease over 
160 min (E). The curves representing the unknown compounds had inflection points suggesting 
that these are unstable compounds. 
Figure 6. PGH2 decomposition curve in Tris•HCl buffer at pH 8 and 37°C (time points 1, 2, 
3, 5, 7, 10, 15, 25, 40 min). Based on this curve, the half-life of PGH2 was determined to be 5 
min. 
Figure 7. PGs formation from PGH2 under different conditions. The initial concentration of 
PGH2 was 2 μM; and the GSH and H2O2 concentrations were 1 mM for H-PGDS and L-PGDS 
or 2.5 mM for mPGES-1.  mPGES-1, H-PGDS, and L-PGDS (units/µL); CAY10526, 
CAY10589, HQL-79, and AT-56 (µM). All values are mean ± SD, n=3. 
Figure 8. The effects on PGE2 and PGD2 formation from 2 μM PGH2 of different ratios of 
mPGES-1 and H-PGDS (A), or mPGES-1 and L-PGDS (B). PGE2 formation increased when the 
proportion of mPGES-1 was increased; and PGD2 formation increased when the proportion of H-
PGDS or L-PGDS was increased. All values are expressed as the mean ± SD, n=3. 
*: p < 0.05, significant differences in PGE2 formation compared with mPGES-1 (0.3 
units/µL)/H-PGDS (0.01 units/µL) (A) and mPGES-1 (0.3 units/µL)/L-PGDS (0.1 units/µL) (B). 
#: p < 0.05, significant differences in PGD2 formation compared with mPGES-1 (0.3 




Figure 9. The consequences of adding different concentrations of the H-PGDS selective 
inhibitor HQL-79 (A) or L-PGDS selective inhibitor AT-56 (B) to a system containing 
equivalent volumes of mPGES-1 (3 units/μL) and H-PGDS (0.1 unit/μL) or L-PGDS (1 unit/μL) 
incubated with 2 μM substrate PGH2. All the values are expressed as mean ± SD, n=3. *: p < 
0.05, significant differences in PGE2 formation compared without addition of HQL-79 (A) or 
without addition of AT-56 (B). PGE2 formation increased while PGD2 formation decreased with 
increasing concentrations of HQL-79 or AT-56. 
#: p < 0.05, significant differences in PGD2 formation compared without addition of HQL-79 (A) 
or without addition of AT-56 (B).  
Figure 10. The effect of the H-PGDS selective inhibitor HQL-79 on the LPS-stimulated 
production of PGE2 and PGD2 from BMDM (A). Values are the mean ± SD, n=3. *: p < 0.05, 
significant differences in PGE2 formation compared with no HQL-79 addition; #: p < 0.05, 
significant differences in PGD2 formation compared with no HQL-79 addition. PGE2 formation 
increased and PGD2 formation decreased with increasing concentrations of HQL-79.  
Examples of LC-MS/MS analyses of PGE2 and PGD2 extracted from BMDM after treatment 




Table 1. PGs formation from PGH2 incubated with or without GSH and various enzymes. All 
values are mean ± SD, n=3. GSH at 2.5 mM was used for control and mPGES-1 incubations, 
while 1 mM GSH was used for incubations with H-PGDS and L-PGDS. 
GSH addition 
PGs formation, % (n=3) 
PGE2 PGD2 
Control w/o GSH 44.3 ± 3.6 14.9 ± 1.5 
Control w/ GSH 42.7 ± 2.9 24.2 ± 3.1 
mPGES-1 w/o GSH 50.1 ± 3.3 14.7 ± 2.1 
mPGES-1 w/ GSH 51.8 ± 3.4 15.1 ± 2.0 
H-PGDS w/o GSH 42.4 ± 4.0 15.7 ± 3.2 
H-PGDS w/ GSH 20.1 ± 2.1 48.0 ± 2.3 
L-PGDS w/o GSH 19.7 ± 1.6 49.8 ± 3.1 





Table 2. The effects of mPGES-1 inhibitors CAY10526 and CAY10589, H-PGDS inhibitor 
HQL-79, and L-PGDS inhibitor AT-56 on conversion of PGH2 to PGE2 and PGD2 by mPGES-1, 





PGs formation (% yield from initial 2 µM PGH2) 
mPGES-1 (3 units/µL) H-PGDS (0.1 unit/µL) L-PGDS (1 unit/µL) 
PGE2 PGD2 PGE2 PGD2 PGE2 PGD2 
No inhibitor 53.5 ± 3.7a 15.1 ± 0.9 20.3 ± 2.1 48.1 ± 3.0 18.2 ± 2.7 50.1 ± 2.8 
CAY10526 
(300 µM) 
45.2 ± 2.5 24.9 ± 2.0 37.8 ± 1.8 26.7 ± 1.3 38.9 ± 2.6 28.1 ± 2.4 
CAY10589 
(100 µM) 
44.9 ± 2.8 25.5 ± 1.6 40.8 ± 3.1 24.2 ± 1.8 40.4 ± 3.4 23.7 ± 0.8 
HQL-79 
(50 µM) 54.4 ± 2.1 14.6 ± 1.0 
38.3 ± 2.0 26.4 ± 1.7 20.4 ± 1.5 49.1 ± 1.8 
AT-56 
(100 µM) 55.1 ± 3.4 14.7 ± 1.6 21.2 ± 1.4 47.3 ± 2.5 
39.8 ± 2.2 24.1 ± 1.3 
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